Loading
Thyroid Cancer Diagnosis and Treatment / Advances in Oncology and Radiotherapy · Journal article
Frontiers in Oncology · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a descriptive retrospective analysis of 30 years of publicly funded thyroid cancer research investment through the NCI, characterizing trends in funding volume, research stage, disease subtypes, molecular targets and thematic evolution. It documents that NCI-administered thyroid cancer research funding peaked in 2015 at USD 24.8 million and shows a documented shift toward translational, molecularly informed and clinically oriented work, but generates no new empirical evidence about the effectiveness of any intervention or the outcomes of any patient population.
Longitudinal portfolio analysis of administrative records. NCI-administered thyroid cancer research projects identified from NIH RePORTER for fiscal years 1996–2025.. Intervention: Not applicable; this is a portfolio analysis of funded research projects, not a study of an intervention in patients.. Compared with: Not applicable; descriptive analysis with no experimental comparator.. n = 753. United States (NCI-administered funding)..
NCI-administered thyroid cancer research funding totalled approximately USD 343.8 million in cumulative BRDPI-adjusted 2025 U.S. dollars from 1996 to 2025. Annual research activity peaked in 2015 with 53 active award-years and approximately USD 24.8 million in BRDPI-adjusted 2025 U.S. dollars. Translational or mixed clinical–preclinical research accounted for 46.5% of the portfolio; R01 awards were the dominant funding mechanism at 48.5%.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This analysis provides no guidance for clinical practice or individual patient care. It may inform research funding institutions about historical trends and research community priorities in thyroid oncology, but it does not evaluate whether funded research has yielded effective interventions or improved patient outcomes.
This is a descriptive portfolio analysis of research funding trends using administrative data; it characterizes what has been funded rather than testing clinical or scientific hypotheses, and generates no outcome data or efficacy evidence.
As stated by the source record.
Quoted from the source exactly as published.
This analysis provides no guidance for clinical practice or individual patient care. It may inform research funding institutions about historical trends and research community priorities in thyroid oncology, but it does not evaluate whether funded research has yielded effective interventions or improved patient outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Thyroid cancer research has shifted over the past three decades toward molecular classification, precision diagnostics and targeted therapy. However, the evolution of public research investment in this field has not been systematically characterized. This study analyzed National Cancer Institute (NCI)-administered thyroid cancer research funding from 1996 to 2025. Methods We performed a longitudinal portfolio analysis of NIH RePORTER records from fiscal years 1996–2025. NCI-administered projects with explicit thyroid cancer research relevance were identified through review of project titles, abstracts, public health relevance statements and project terms. The final analytic cohort comprised 753 project-award years (AYs). Rule-based dictionaries were used to annotate research stage, disease subtype, molecular target and therapeutic or diagnostic modality. Deduplicated project text was further analyzed using MedCPT biomedical embeddings and BERTopic to identify higher-order thematic domains. Results The cohort represented approximately USD 343.8 million in cumulative NCI funding in BRDPI-adjusted 2025 U.S. dollars. Annual research activity increased over time, peaking in 2015 with 53 active AYs and approximately USD 24.8 million in BRDPI-adjusted 2025 U.S. dollars. Translational or mixed clinical–preclinical research accounted for the largest share of the portfolio (46.5%), and R01 awards were the dominant funding mechanism (48.5%). Papillary thyroid carcinoma was the most frequently annotated subtype, followed by anaplastic, differentiated, follicular, poorly differentiated and medullary thyroid cancers. BRAF, RET, MAPK/MEK, PI3K/AKT/mTOR and RAS were the leading molecular targets. Topic modelling identified five higher-order thematic domains, suggesting a relative shift from broad thyroid cancer characterization toward diagnosis and risk stratification, molecular signaling, treatment-response biology and therapeutics for aggressive or advanced disease. Conclusions NCI-administered thyroid cancer research funding expanded between 1996 and 2025 and became increasingly translational, molecularly informed and clinically oriented. These findings provide an empirical map of public research investment in thyroid oncology and may help inform future funding priorities.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.